Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment. Recently approved drugs, pegcetacoplan and avacincaptad pegol, target the complement system to slow dry AMD progression.
Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment. Recently approved drugs, pegcetacoplan and avacincaptad pegol, target the complement system to slow dry AMD progression.